What is Levorexant?
There appears to be confusion in the question: "levorexant" does not exist as an insomnia medication—you may be asking about either "lemborexant" (a dual orexin receptor antagonist for insomnia) or "levorphanol" (an opioid analgesic for pain). These are completely different medications with entirely different uses.
If You Mean Lemborexant (for Insomnia):
Lemborexant is a dual orexin receptor antagonist (DORA) approved for treating insomnia disorder in adults, characterized by difficulties with sleep onset and/or sleep maintenance 1. It works by blocking overactive orexin signaling that keeps people awake, thereby promoting sleep 2.
Mechanism and Clinical Use
- Blocks both orexin receptor types (OXR1 and OXR2) with greater affinity for OXR2, which regulates wakefulness 1
- Available in 5 mg and 10 mg doses for oral administration 2
- Approved in the USA (December 2019) and Japan (January 2020) 1
Efficacy Profile
Lemborexant demonstrates robust efficacy across multiple sleep parameters 3, 4:
- Reduces sleep onset latency by approximately 10-13 minutes compared to placebo 2
- Decreases wake after sleep onset (WASO) by approximately 19-22 minutes 2
- Improves sleep efficiency by 6-7% 2
- Effective for both sleep initiation and maintenance, including early morning awakenings 5
Both 5 mg and 10 mg doses show similar efficacy, though the 10 mg dose may provide slightly greater improvements 2.
Safety and Tolerability
Lemborexant has a favorable safety profile compared to traditional hypnotics 4, 6:
- Most common adverse effect: somnolence (daytime sleepiness), occurring more frequently than placebo 2
- Minimal next-morning residual effects on alertness or cognitive function 7, 6
- No significant cognitive or psychomotor impairment unlike benzodiazepines or Z-drugs 4
- No complex sleep-related behaviors (sleepwalking, sleep-driving) observed in trials 4
- Low risk of dependence, withdrawal symptoms, or falls 6
- Safe in older adults and patients with mild obstructive sleep apnea 7, 6
Clinical Context
While lemborexant is not specifically mentioned in the 2017 AASM guidelines 8 (as it was approved in 2019), suvorexant—another orexin receptor antagonist—received a WEAK recommendation for sleep maintenance insomnia 8. The guidelines note that eszopiclone, zolpidem, and suvorexant showed small but significant improvements in sleep outcomes 9.
Lemborexant represents an advancement over earlier hypnotics, particularly for patients who cannot tolerate the cognitive impairment, falls risk, or dependence associated with benzodiazepines and Z-drugs 4, 6. It is especially appropriate for geriatric patients who are more sensitive to these adverse effects 4.
Practical Considerations
- Start with 5 mg to minimize somnolence risk, especially in patients at risk for excessive daytime sleepiness 2
- Can be used long-term with sustained efficacy 5
- Quick onset with steep decline in plasma levels helps minimize morning effects despite long terminal half-life 6
If You Mean Levorphanol (for Pain):
Levorphanol is a potent opioid analgesic (mu-opioid receptor agonist) used for moderate to severe pain, NOT for insomnia 10. It is 4-8 times more potent than morphine with a long half-life of 11-16 hours 10.
This medication carries significant risks including respiratory depression, CNS depression, addiction potential, and typical opioid adverse effects (nausea, vomiting, constipation, sedation) 10. It is completely unrelated to insomnia treatment.
Clarify which medication you are asking about, as these are entirely different drugs with different indications.